Sterling Capital Management LLC lowered its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 20.7% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 52,581 shares of the conglomerate's stock after selling 13,739 shares during the period. Sterling Capital Management LLC's holdings in Danaher were worth $11,649,000 as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. bought a new stake in shares of Danaher in the second quarter worth $10,492,520,000. Wellington Management Group LLP increased its holdings in Danaher by 10.4% in the 2nd quarter. Wellington Management Group LLP now owns 16,316,834 shares of the conglomerate's stock worth $3,108,031,000 after acquiring an additional 1,542,310 shares in the last quarter. Jupiter Topco LLC bought a new position in Danaher in the 2nd quarter worth $1,456,317,000. Generation Investment Management LLP bought a new stake in Danaher during the second quarter valued at about $1,287,949,000. Finally, Bank of America Corp DE bought a new position in Danaher in the 2nd quarter worth approximately $993,846,000. Hedge funds and other institutional investors own 79.05% of the company's stock.
More Danaher News
Here are the key news stories impacting Danaher this week:
- Positive Sentiment: Danaher reported third-quarter adjusted earnings of $2.11 per share, above the $1.92 analyst consensus, while revenue reached approximately $6.55 billion. Revenue increased 8.3% year over year, and management raised its full-year 2026 adjusted EPS outlook. Danaher 3Q Net Up Sharply as Company Boosts 2026 Adjusted EPS View
- Positive Sentiment: Analysts raised their valuation targets following the results. TD Cowen and JPMorgan lifted targets to $270, Goldman Sachs raised its target to $275, Stifel increased its target to $260, and Robert W. Baird raised its target to $254. The firms maintained bullish ratings, including Buy, Overweight and Outperform. Danaher Analysts Raise Their Forecasts Following Better-Than-Expected Q3 Earnings
- Positive Sentiment: Management highlighted margin strength, improved execution and an increased focus on innovation and artificial intelligence, factors analysts viewed as supporting a better longer-term outlook. Danaher Earnings Call Highlights Margin Strength, AI Push
- Neutral Sentiment: Despite the earnings beat and higher targets, shares declined in the immediate post-results reaction, suggesting investors may have already priced in much of the improvement. A recent valuation comparison also frames DHR as a stock for investors weighing quality and growth against its relatively elevated valuation. Danaher Q3 Recap: Decent Results, Still A Hold
- Negative Sentiment: Danaher’s new CEO emphasized the need for better execution and innovation. TD Cowen cited tariff pressure and a cautious 2027 outlook, creating uncertainty beyond the raised 2026 guidance and helping explain why the stock did not fully respond to the strong quarterly report. Danaher Posts First Earnings Under New CEO
Wall Street Analysts Forecast Growth
A number of research firms have recently commented on DHR. Stifel Nicolaus increased their target price on Danaher from $220.00 to $260.00 and gave the company a "buy" rating in a research report on Thursday. Barclays boosted their price objective on Danaher from $255.00 to $260.00 and gave the company an "overweight" rating in a report on Thursday. Robert W. Baird raised their target price on shares of Danaher from $246.00 to $254.00 and gave the stock an "outperform" rating in a research report on Thursday. Morgan Stanley upped their price objective on shares of Danaher from $220.00 to $240.00 and gave the stock an "overweight" rating in a research note on Monday, October 12th. Finally, Guggenheim upped their target price on Danaher from $200.00 to $250.00 and gave the stock a "buy" rating in a report on Thursday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have given a Hold rating to the company. According to MarketBeat, Danaher has an average rating of "Moderate Buy" and an average target price of $242.91.
Check Out Our Latest Stock Analysis on DHR
Danaher Stock Performance
Shares of NYSE DHR traded up $0.61 during mid-day trading on Friday, hitting $230.36. The stock had a trading volume of 3,935,897 shares, compared to its average volume of 4,912,513. The company has a 50 day moving average of $216.32 and a two-hundred day moving average of $197.35. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.25 and a current ratio of 1.63. The firm has a market cap of $161.94 billion, a PE ratio of 37.70, a PEG ratio of 2.87 and a beta of 0.76. Danaher Corporation has a twelve month low of $160.93 and a twelve month high of $242.80.
Danaher (NYSE:DHR - Get Free Report) last issued its earnings results on Wednesday, October 21st. The conglomerate reported $2.11 EPS for the quarter, beating analysts' consensus estimates of $1.92 by $0.19. Danaher had a return on equity of 11.17% and a net margin of 16.91%. The firm had revenue of $6.55 billion for the quarter, compared to analyst estimates of $6.56 billion. During the same quarter in the prior year, the firm earned $1.89 earnings per share. Danaher's revenue for the quarter was up 8.3% on a year-over-year basis. Research analysts predict that Danaher Corporation will post 8.59 EPS for the current fiscal year.
Danaher Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a $0.40 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. Danaher's dividend payout ratio is presently 26.19%.
About Danaher
(
Free Report)
Danaher Corporation NYSE: DHR is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.
The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.